{"id":"NCT04422561","sponsor":"Zagazig University","briefTitle":"Prophylactic Ivermectin in COVID-19 Contacts","officialTitle":"Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-05-31","primaryCompletion":"2020-07-14","completion":"2020-07-27","firstPosted":"2020-06-09","resultsPosted":"2020-08-27","lastUpdate":"2020-08-27"},"enrollment":340,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["COVID"],"interventions":[{"type":"DRUG","name":"Ivermectin Tablets","otherNames":[]}],"arms":[{"label":"Ivermectin group","type":"EXPERIMENTAL"},{"label":"Control group","type":"NO_INTERVENTION"}],"summary":"asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \\& diagnosis of COVID -19","primaryOutcome":{"measure":"Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)","timeFrame":"within 14 days after enrollement","effectByArm":[{"arm":"Ivermectin Group","deltaMin":15,"sd":null},{"arm":"Control Group","deltaMin":59,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Egypt"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":203},"commonTop":["diarrhea","nausea","fatigue","burning sensation","tingling/numbness"]}}